Physician profile
Horace Tang
NPI 1073833984
$14,670.47
in general payments reported to CMS, 2019-2025
54 companies · $1,082 in 2025
The $1,082 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,043 · 2020: $3,499 · 2021: $930 · 2022: $2,055 · 2023: $2,845 · 2024: $2,217 · 2025: $1,082.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,640 · Consulting Fee: $2,313 · Education: $191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,640.18 |
| Consulting Fee | $2,312.50 |
| Education | $191.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $5,085.79 | 2019-2025 | Calquence, Lynparza, Imfinzi |
| Daiichi Sankyo INC. | $1,776.02 | 2020-2025 | Vanflyta, Injectafer |
| E.R. Squibb & Sons, L.L.C. | $599.72 | 2019-2024 | Opdualag, Opdivo |
| Astellas Pharma US INC | $576.66 | 2019-2024 | Padcev, Xospata |
| Novartis Pharmaceuticals Corporation | $473.60 | 2019-2024 | |
| Gilead Sciences, INC. | $443.99 | 2019-2024 | Trodelvy |
| Pfizer INC. | $442.27 | 2019-2024 | |
| Genentech USA, INC. | $398.42 | 2019-2023 | Venclexta, Phesgo, Perjeta |
| Janssen Biotech, INC. | $346.72 | 2019-2024 | Erleada, Darzalex, Tecvayli |
| Celgene Corporation | $330.86 | 2022-2024 | Reblozyl, Pomalyst, Opdualag |
| Eisai INC. | $305.06 | 2020-2024 | |
| Incyte Corporation | $302.54 | 2019-2024 | Jakafi |
| Cardinal Health 110 LLC | $275.00 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $242.42 | 2019-2024 | Alunbrig |
| Lilly USA, LLC | $221.37 | 2019-2023 | Verzenio, Jaypirca, Retevmo |
Show all 53 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tesaro, INC. | $213.72 | 2019 | |
| Covis Pharma Gmbh | $200.00 | 2021 | |
| Merck Sharp & Dohme LLC | $197.92 | 2019-2023 | Keytruda, Lynparza |
| Abbvie INC. | $178.15 | 2024 | |
| Rigel Pharmaceuticals, INC. | $175.26 | 2019-2023 | Tavalisse, Rezlidhia |
| Seagen INC. | $163.00 | 2020-2023 | Padcev, Adcetris |
| Amgen INC. | $152.47 | 2020-2023 | Vectibix, Nplate, Xgeva |
| Regeneron Healthcare Solutions, INC. | $139.63 | 2022-2024 | Libtayo |
| Aveo Pharmaceuticals, INC. | $132.50 | 2023 | Fotivda |
| Pharmacosmos Therapeutics INC. | $115.21 | 2021-2023 | Monoferric |
| Janssen Scientific Affairs, LLC | $108.11 | 2025 | Talvey, Tecvayli, Carvykti |
| Foundation Medicine, INC. | $100.00 | 2019 | |
| Myriad Genetic Laboratories, INC. | $88.48 | 2023 | Myrisk |
| Bayer Healthcare Pharmaceuticals INC. | $79.69 | 2019-2024 | |
| Glaxosmithkline, LLC. | $75.11 | 2022-2024 | Jemperli, Zejula |
| Exelixis INC. | $60.74 | 2019-2024 | Cabometyx |
| Mirati Therapeutics, INC. | $60.05 | 2023-2024 | Krazati |
| Puma Biotechnology, INC. | $59.00 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $47.27 | 2023-2024 | Orgovyx |
| Emd Serono, INC. | $45.42 | 2023-2024 | Bavencio |
| Pharmaessentia USA Corporation | $45.36 | 2023-2024 | Besremi |
| Myovant Sciences INC. | $45.13 | 2022 | |
| Genzyme Corporation | $42.99 | 2021 | |
| Sobi, INC | $41.26 | 2022-2023 | |
| Kite Pharma, INC. | $39.64 | 2023 | Yescarta |
| Pharmacyclics LLC, An Abbvie Company | $31.05 | 2023 | Imbruvica, Epkinly |
| Blueprint Medicines Corporation | $27.90 | 2023-2024 | Ayvakit |
| Janssen Pharmaceuticals, INC | $25.20 | 2019-2023 | Xarelto |
| Adc Therapeutics America, INC. | $23.09 | 2023 | |
| Amarin Pharma, INC. | $18.18 | 2021 | |
| Beigene USA, INC. | $17.16 | 2022 | |
| Servier Pharmaceuticals LLC | $16.83 | 2023 | |
| Array Biopharma INC | $15.00 | 2021 | |
| Eusa Pharma (US) LLC | $14.98 | 2021 | |
| Kyowa Kirin, INC. | $14.95 | 2020 | |
| Jazz Pharmaceuticals INC. | $14.87 | 2021 | |
| Taiho Oncology, INC. | $14.81 | 2020 | |
| Veracyte, INC. | $9.90 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Horace Tang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.